GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Beginning Cash Position

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Beginning Cash Position : $1.52 Mil (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Beginning Cash Position?

Innovation Pharmaceuticals's Beginning Cash Position for the quarter that ended in Sep. 2023 was $1.52 Mil.

Innovation Pharmaceuticals's quarterly Beginning Cash Position declined from Mar. 2023 ($2.42 Mil) to Jun. 2023 ($1.94 Mil) and declined from Jun. 2023 ($1.94 Mil) to Sep. 2023 ($1.52 Mil).

Innovation Pharmaceuticals's annual Beginning Cash Position increased from Jun. 2021 ($6.02 Mil) to Jun. 2022 ($10.19 Mil) but then declined from Jun. 2022 ($10.19 Mil) to Jun. 2023 ($3.81 Mil).


Innovation Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for Innovation Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals Beginning Cash Position Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.42 0.58 6.02 10.19 3.81

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 2.97 2.42 1.94 1.52

Innovation Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Innovation Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Executives
Arthur Peter Bertolino officer: Pres. & Chief Medical Officer C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness officer: Vice President 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin director C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor director 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter director 7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich director, 10 percent owner, officer: Chief Financial Officer C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon director, 10 percent owner, officer: President-Chief Scient.Officer 10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans director, officer: Chief Executive Officer 17 IRVING PLACE, PELHAM NY 10803

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Headlines

From GuruFocus

Innovation Pharmaceuticals Provides Brilacidin Program Update

By ACCESSWIRE ACCESSWIRE 11-18-2021